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Beijing Type  
Mutation Frequency
To the Editor: A striking finding 
in the study by de Steenwinkel et al. 
(1) is the high frequency of mutation 
to rifampin resistance by 2 Mycobac-
terium tuberculosis Beijing strains, 
which might play a role in the associ-
ation between the Beijing strains and 
multidrug-resistant tuberculosis. Ear-
lier reported frequency of mutation to 
rifampin resistance by M. tuberculo-
sis has been 10−8 CFU (2,3), includ-
ing the Beijing genotype (3,4). Of 
note, the Beijing 2002–1585 strain, 
for which frequency of mutation to 
rifampin resistance is 10-3 CFU (1 
mutant/1,000 CFU), showed a mod-
erate frequency of 10−8 CFU in anoth-
er study (4). We think that a mutation 
frequency increase of 100,000× is re-
markably high. In contrast, rifampin-
resistant mutants of the Beijing 1585 
strain did not emerge in low-density 
cultures (5 × 105 CFU/mL) used for 
time-kill kinetics experiments, al-
though frequency of mutation to ri-
fampin resistance was determined to 
be 10-3 CFU.
Mutation frequency is deter-
mined by fluctuation assays. To ex-
clude preexisting mutants, which 
would bias the mutation frequency by 
so-called jackpots, a series of low-in-
oculum cultures is typically used (5). 
However, for unknown reasons, de 
Steenwinkel et al. used only 1 high-
density culture of 1010 CFU of each 
strain to determine mutation frequen-
cy. This strategy is not recommended 
because mutations can occur early 
or late, resulting in substantial mu-
tation frequency fluctuation between 
test episodes. A strain with known 
mutation rates should preferably be 
included to rule out possible techni-
cal errors.
We propose the following expla-
nations for the remarkable results: 1) 
the rifampin concentration for select-
ing mutants might have been too low, 
enabling growth of some colonies of 
drug-susceptible bacteria; 2) rifampin 
mutants arose early or preexisted 
in the cultivation of Beijing strains 
1585 and 1607, producing jackpots; 
or 3) the 2 Beijing isolates might 
contain rifampin-resistant subpopula-
tions (heteroresistance). The capacity 
of the Beijing strain to develop and, 
especially, transmit multidrug-resis-
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In Response: We explain the 
differing frequencies of mutation 
to rifampin resistance mentioned 
by Werngren (1). First, the strains 
of Mycobacterium tuberculosis that 
we tested differed from those previ-
ously tested (2). Second, we used 
different rifampin concentrations in 
subculture plates. For Beijing strain 
2002–1585, Bergval et al. (3) found 
a mutation frequency of 4–24 × 10−8 
at a subculture concentration of 8 
mg/L, whereas we found a mutation 
frequency of 3–4 × 10−3 at a subcul-
ture concentration of 1 mg/L and a 
lower mutation frequency at 2 mg/L. 
Thus, the concentration of drugs in 
subculture plates is crucial to mutation 
frequency assays. Absent a subculture 
concentration standard, we applied ri-
fampin at 1 mg/L (4) because bacteria 
growing at this concentration are con-
sidered resistant to rifampin. Our mu-
tation frequency and time-kill kinet-
ics assay results are not contradictory 
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